NEW ENGLAND SKC-2641 UNDER CONTRACT

NEW ENGLAND SKC-2641 UNDER CONTRACT

 Home Health

  • Independent home health provider
  • $16.8M LTM in revenue with 13.1% EBITDA
  • Organic growth of 16.7% over the last 3 years
  • 44% traditional Medicare, 49% Medicare Advantage, 4% Medicaid
  • Average daily census of nearly 800 patients
  • Highly qualified and deep management team throughout the organization
  • Exceptional track record on all audits; Quality of Earnings analysis complete
  • Listing ID: 18463
  • Categories: Home Health
  • Status: Under Contract
Contact details

Northeast [email protected]

Contact listing owner

Featured Insights

Stoneridge Partners gives you the latest news and updates for market developments, financial indicators, and other indicators that give our clients an edge.

Confessions of a Former Operator: Why Surviving the Home Health Headwinds Now Demands Platform Scale

By |September 8th, 2026|Blog|

The clinical mission of post-acute care is beautiful, but the operational math is fundamentally broken for independent providers. I don't say this lightly, nor do I say it as an outsider looking at spreadsheets. For more than 10 years, I lived and b [...]

The 24-Month Behavioral Health Outlook: Transitioning from Multiple Arbitrage to Operational Excellence

By |September 1st, 2026|Blog|

Over the next 24 months, behavioral health will reward operators who run tight, disciplined businesses — not just those who grow fast. The old playbook of buying up fragmented clinics, loosely branding them, and flipping them for a quick multiple is [...]

Is Now a Good Time to Think About Selling My Home Care Company?

By |August 11th, 2026|Blog|

Yes. In fact, the summer months may be one of the best times for home care agency owners to begin preparing for a potential sale. Buyer interest in quality home care companies remains strong, and strategic buyers, private equity-backed organizations, [...]

Considering The Sale Of Your Business?
Questions About Your Valuation Or An Optimal Exit Strategy?

Get a confidential valuation from one of our market-leading M&A advisors.

2026-07-13T20:07:29-04:00By |

Share This Article

Go to Top